GROWTH
Top line decelerating.
+4.1% YoY versus +7.4% prior. 3y CAGR +5.8%.
+4.1%
Chemed Corporation CHE
Healthcare · Market Cap: $5.8B
$436.27▲ 0.24 (0.06%)
Fundamentals as of 2025-12-31
We use cookies
MainRatios uses cookies for essential site functions. With your consent, we also use analytics cookies including session replay sampling (PostHog, Google Analytics) and advertising cookies (Google AdSense). You can reject non-essential cookies, including the "sale" or sharing of personal information under CCPA, and you may withdraw consent at any time (GDPR). See our Privacy Policy for details.
Healthcare · Market Cap: $5.8B
Fundamentals as of 2025-12-31
All analysis on this page is for educational purposes only and does not constitute financial advice. Fair values are model-based estimates. Always do your own research.
The Question
1 of 2 legendary models say AVOID CHE — but Warren Buffett disagrees.
What would legendary investors pay for CHE?
These figures are not quotes or opinions from Buffett, Graham, Lynch or the other investors. They are our own estimates, computed by applying the intrinsic-value formulas each investor is known for to this company’s financials.
For educational purposes only. Not a recommendation to buy or sell securities.
Yes — Chemed Corporation's 27.1% ROE ranks above the S&P 500 median, and D/E 0.67 stays within healthy bounds.
Financial story
Yes — Chemed Corporation's 27.1% ROE shows strong capital efficiency, and its 0.67 debt-to-equity stays within healthy bounds.
Bottom line: CHE is rated BUY by 1 of 2 legendary models, with 1 holding and 0 flagging it overvalued, but earns a C sector grade (53/100) in Healthcare. Whether the premium is justified depends on which lens you trust. Drill into the valuation breakdown and sector ranking for the full picture.
CHE's earnings calendar and history are tracked in the financials tab. Specific dates depend on company-published guidance.
CHE is in the Healthcare sector. Sector ranking and peer comparison are in the sector tab.
0 of 2 legendary investor models rate CHE a BUY. Fair value estimates and full investor breakdown are in the valuation tab.
Average fair value across qualifying models: $451. See the per-investor fair-value table in the valuation tab.
CHE trades at 20.7x earnings. Sector context and per-investor signals are in the valuation tab.
CHE and BRKR differ on P/E, ROE, and revenue growth. See the full CHE vs BRKR compare matrix.
+4.1% YoY versus +7.4% prior. 3y CAGR +5.8%.
+4.1%Net margin 10.5% versus 12.4% prior (−1.9pp). Operating 13.4%.
10.5%P/E 24.1x — 15% below the 5y median of 28.3x. Forward 17.9x hints at EPS expansion next year.
How does CHE compare?
See exactly where CHE ranks
Sign in to unlock the full sector ranking — free.
Sign in to see the rankingCHE sits at #42 in Healthcare with a C grade (53/100).
